Evaluation of Drug-Drug Interaction Risk with PBPK Models
Publisher
John Wiley & Sons, Inc.
Reference88 articles.
1. Drug-drug interactions via mechanism-based cytochrome P450 inactivation: Points to consider for risk assessment from in vitro data and clinical pharmacologic evaluation;Venkatakrishnan;Curr Drug Metab.,2007
2. Inactivation of monoamine oxidase A by the monoamine oxidase B inactivators 1-phenylcyclopropylamine, 1-benzylcyclopropylamine, and N-cyclopropyl-alpha-methylbenzylamine;Silverman;Biochemistry.,1988
3. Mechanism-based inactivation of cyto-chrome P450 enzymes: Chemical mechanisms, structure-activity relationships and relationship to clinical drug-drug interactions and idiosyncratic adverse drug reactions;Kalgutkar;Curr Drug Metab.,2007
4. Time-dependent CYP inhibition;Riley;Expert Opin Drug Metab Toxicol.,2007
5. Mechanism-based inactivation of human cytochromes p450s: Experimental characterization, reactive intermediates, and clinical implications;Hollenberg;Chem Res Toxicol.,2008